Medicare raises oxygen supplier payments, mandates beneficiary protections

What it does

The SOAR Act reforms Medicare's payment and coverage rules for supplemental oxygen equipment and services. It raises reimbursement rates for liquid oxygen to 200% of 2015 baseline (adjusted annually for inflation), requires suppliers to provide comprehensive services (delivery, setup, 24-hour support, portable equipment access), adds a new payment for respiratory therapist involvement, standardizes medical-necessity documentation via electronic templates, and establishes explicit beneficiary rights (choice of supplier, clear communication, grievance protections, timely notice of cost-sharing end). The bill aims to improve access and quality of care while protecting beneficiaries from supplier abuse.

Why we flagged it

The bill's core mechanism is a dual reform: raising oxygen supplier reimbursement rates and mandating supplier accountability through beneficiary rights, clinical documentation standards, and fraud controls. It is not a simple rate increase (which would be 'Oxygen Reimbursement Increase') nor a pure beneficiary-protection measure, but a structured trade-off between higher payments and stricter operational requirements.

What the text implies

• The 200% interim payment rate (2015 baseline + CPI 2016–2025) may exceed current market rates for some suppliers, creating windfall gains during the transition period before permanent rates are set.
• Respiratory therapist add-on payments are 'non-budget neutral,' meaning they are not offset by reductions elsewhere—this increases total Medicare spending on oxygen services without explicit appropriation cap.

The full analysis lists 5 implications of this text.

Who stands to gain

oxygen equipment suppliers; respiratory therapists and respiratory therapy services; durable medical equipment (DME) providers